Patient characteristics
| . | Value . |
|---|---|
| Male-to-female ratio | 111:71 |
| Median age at ASCT, y (range) | 58.5 (26.7-72.4) |
| Disease status at ASCT | |
| Chemosensitive disease, n | 149 |
| Chemo-refractory disease/progressive disease, n | 33 |
| Induction chemotherapy | |
| VAD, n | 97 |
| CTD, n | 47 |
| Z-Dex, n | 34 |
| ABCM, n | 1 |
| Melphalan, n | 1 |
| Cyclophosphamide/prednisolone, n | 2 |
| Disease subtype | |
| IgG, n | 102 |
| IgA, n | 35 |
| IgD, n | 13 |
| Light chain myeloma, n | 21 |
| Nonsecretory, n | 11 |
| Median β2M level at ASCT, mg/L (range) | 2.0 (0.9-13) |
| Median serum albumin level at6 ASCT, g/L (range) | 3.7 (2.4-4.8) |
| Median plasma cell percentage at ASCT, %(range) | 10 (0-90) |
| Median CD34 cell dose, × 106/kg (range) | 3.4 (1.7-19.2) |
| . | Value . |
|---|---|
| Male-to-female ratio | 111:71 |
| Median age at ASCT, y (range) | 58.5 (26.7-72.4) |
| Disease status at ASCT | |
| Chemosensitive disease, n | 149 |
| Chemo-refractory disease/progressive disease, n | 33 |
| Induction chemotherapy | |
| VAD, n | 97 |
| CTD, n | 47 |
| Z-Dex, n | 34 |
| ABCM, n | 1 |
| Melphalan, n | 1 |
| Cyclophosphamide/prednisolone, n | 2 |
| Disease subtype | |
| IgG, n | 102 |
| IgA, n | 35 |
| IgD, n | 13 |
| Light chain myeloma, n | 21 |
| Nonsecretory, n | 11 |
| Median β2M level at ASCT, mg/L (range) | 2.0 (0.9-13) |
| Median serum albumin level at6 ASCT, g/L (range) | 3.7 (2.4-4.8) |
| Median plasma cell percentage at ASCT, %(range) | 10 (0-90) |
| Median CD34 cell dose, × 106/kg (range) | 3.4 (1.7-19.2) |
ASCT indicates autologous stem cell transplantation; VAD, vincristine, Adriamycin, dexamethasone; CTD, cyclophosphamide, thalidomide, dexamethasone; Z-Dex, idarubicin, dexamethasone; ABCM, Adriamycin, carmustine, cyclophosphamide, and melphalan; IgG, immunoglobulin G; and β2M, β-2 microglobulin.